Targeting FGFR changes in advanced, hard-to-treat cancers
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed advanced (metastatic), returning, or hard-to-remove solid cancer
- Your cancer got worse or did not respond to the first treatment, or no standard option is available
- Your tumor must have an FGFR gene change found by an approved DNA test (NGS)
- You can provide an existing tumor tissue sample or agree to a new biopsy
- Your overall health is generally good enough for study treatment (ECOG 0–1 for most people; KPS ≥70 for primary brain tumors)
- Your blood and body chemistry levels meet key limits (for example corrected calcium and phosphate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (3HP-2827) for people with solid tumors that have spread or can't be removed surgically, and have changes in a gene called FGFR2. The goal is to see if the drug is safe and effective.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
Hear when a new FGFR Gene Alterations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.